EGFR and neoplasm: Current preclinical models for studying EGFR-mutant LUAD include patient-derived cell lines, organoids, and xenograft models, yet these human-derived models cannot form tumors in immunocompetent mice, limiting insights into how EGFR mutations affect tumor-immune interactions.